Molecular Profiling of Endometrial MalignanciesReport as inadecuate

Molecular Profiling of Endometrial Malignancies - Download this document for free, or read online. Document in PDF available to download.

Obstetrics and Gynecology InternationalVolume 2010 2010, Article ID 162363, 16 pages

Review Article

Department of Pathology, University of Texas Health Science Center at San Antonio, San Antonio, TX 78229, USA

Department of Obstetrics and Gynecology, University of Texas Health Science Center at San Antonio, San Antonio, TX 78229, USA

Received 1 October 2009; Revised 9 December 2009; Accepted 14 January 2010

Academic Editor: Paul J. Hoskins

Copyright © 2010 Norasate Samarnthai et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Molecular profiling of endometrial neoplasms reveals genetic changes in endometrial carcinomas that support the dualistic model, in which type I carcinomas are estrogen-dependent, low grade lesions and type II carcinomas are nonestrogen dependent and high grade. The molecular changes in type I endometrial carcinomas include mutations in PTEN, PIK3CA, KRAS, and -catenin, along with microsatellite instability, whereas type II endometrial carcinomas are characterized by genetic alterations in p53, HER2-neu, p16, and E-cadherin. For endometrial neoplasms with a malignant mesenchymal component, C-MYC mutations and loss of heterozygosity are frequently seen in carcinosarcomas, and a fusion gene, JAZF1-JJAZ1, is distinctive for endometrial stromal sarcoma. In addition, p53 mutations may play an important role in tumorigenesis of undifferentiated endometrial sarcoma. These molecular changes can help in the diagnosis of endometrial neoplasms, as well as form the basis of molecular targeted therapy.

Author: Norasate Samarnthai, Kevin Hall, and I-Tien Yeh



Related documents